Objective To observe the clinical efficacy of phentolamine mesilate, thymosin α1 combined with PHGF in the treatment of severe hepatitis.Methods 68 patients with severe hepatitis were randomly divided into two groups: the treatment group (n=42) were treated with 10mg phentolamine mesilate, 160mg hepatocyte growth-promoting factors (PHGF) once daily by intravenous drip, and 1.6mg thymosin α1, two weekly by subcutis.The control group (n=26) was given 160mg PHGF once daily by intravenous drip.Two groups were given other composite treatment.Before and after treatment, blood test, hepatic function and coagulation function of the two groups were detected respectively.Results Serum total bilirubin (TBiL) of the two groups were lower (P<0.01) , prothombin active (PTA) and total cholesterin (Tch) were higher (P<0.01) after treatment.At the end of treatment, TBil was lower, PTA and Tch were higher in the treatment group than that in the control group (P<0.05, P<0.01) .There was no obvious significant different in fatality rate and significant effective rate between the two groups (P>0.05) , but total effective rate of the treatment group was significant higher than that of the control group (P<0.05) .Conclusion Phentolamine mesilate, thymosin α1 combined with PHGF has good clinical efficacy in the treatment of severe hepatitis.
DownLoad: